mebendazole has been researched along with Cancer of Ovary in 3 studies
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.
mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mebendazole was evaluated in cisplatin-resistant high grade serous stage 3C ovarian cancer patient derived xenograft (PDX) models: PDX-0003 (p53 null) and PDX-0030 (p53 positive), and on ovarian cancer cell lines: MES-OV (p53 R282W), ES2 (p53 S241F), A2780 (p53 wild type), SKOV3 parental (p53 null) and isogenic sublines, SKOV3 R273H p53 and SKOV3 R248W p53." | 1.62 | Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. ( Benbrook, DM; Bieniasz, M; Elayapillai, S; Gunderson, CC; Hunsucker, LA; Isingizwe, ZR; Kennedy, AL; Lightfoot, S; Pathuri, G; Ramraj, S; Wang, L; Zhao, YD, 2021) |
| "Ovarian cancer is the third most common cancer and the second most common cause of gynecologic cancer death in women." | 1.62 | Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways. ( Chen, C; Haydon, RC; He, F; He, TC; Huang, L; Liu, Q; Luu, HH; Ni, N; Reid, RR; Shen, L; Shi, D; Tang, L; Wagstaff, W; Wang, H; Zhang, J; Zhao, L, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Elayapillai, S | 1 |
| Ramraj, S | 1 |
| Benbrook, DM | 1 |
| Bieniasz, M | 1 |
| Wang, L | 1 |
| Pathuri, G | 1 |
| Isingizwe, ZR | 1 |
| Kennedy, AL | 1 |
| Zhao, YD | 1 |
| Lightfoot, S | 1 |
| Hunsucker, LA | 1 |
| Gunderson, CC | 1 |
| Huang, L | 1 |
| Zhao, L | 1 |
| Zhang, J | 1 |
| He, F | 1 |
| Wang, H | 1 |
| Liu, Q | 1 |
| Shi, D | 1 |
| Ni, N | 1 |
| Wagstaff, W | 1 |
| Chen, C | 1 |
| Reid, RR | 1 |
| Haydon, RC | 1 |
| Luu, HH | 1 |
| Shen, L | 1 |
| He, TC | 1 |
| Tang, L | 1 |
| Mousa, AM | 1 |
| Mehrez, MG | 1 |
| Muhtaseb, SA | 1 |
| Al-Mudalal, DS | 1 |
| Kamel, SM | 1 |
3 other studies available for mebendazole and Cancer of Ovary
| Article | Year |
|---|---|
Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Repositioning; Drug | 2021 |
Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways.
Topics: Animals; Antinematodal Agents; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell | 2021 |
Disseminated pelvic hydatidosis presenting as ovarian carcinomatosis: successful post-operative treatment with mebendazole.
Topics: Diagnosis, Differential; Echinococcosis; Female; Humans; Mebendazole; Ovarian Neoplasms | 1987 |